Daily Respiratory Research Analysis
Precision respiratory medicine advanced on three fronts: (1) ARDS inflammatory phenotypes dynamically shift over time and predict opposite corticosteroid effects, enabling treatment personalization; (2) a multicenter pragmatic RCT found that driving pressure–targeted high PEEP did not improve and may worsen postoperative respiratory outcomes; and (3) a meta-analysis identified robust risk and protective factors for rapidly progressive ILD in idiopathic inflammatory myopathies.
Summary
Precision respiratory medicine advanced on three fronts: (1) ARDS inflammatory phenotypes dynamically shift over time and predict opposite corticosteroid effects, enabling treatment personalization; (2) a multicenter pragmatic RCT found that driving pressure–targeted high PEEP did not improve and may worsen postoperative respiratory outcomes; and (3) a meta-analysis identified robust risk and protective factors for rapidly progressive ILD in idiopathic inflammatory myopathies.
Research Themes
- ARDS phenotyping and steroid precision therapy
- Perioperative ventilation strategies and patient safety
- Risk stratification for rapidly progressive interstitial lung disease
Selected Articles
1. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality.
Using pooled RCT data to build an open-source AI classifier and validating it in 5,578 patients, the authors show that ARDS inflammatory phenotypes change over time and strongly modify corticosteroid effects: benefit in hyperinflammatory ARDS, harm in hypoinflammatory ARDS. Only patients remaining hyperinflammatory by day 3 maintained a survival benefit from steroids.
Impact: It operationalizes precision medicine in ARDS by providing a practical, open-source tool to monitor phenotypes and tailor corticosteroid therapy, potentially changing practice and trial design.
Clinical Implications: Clinicians should avoid blanket steroid use in ARDS and consider phenotype-guided administration with early reassessment (e.g., by day 3). This approach could reduce harm in hypoinflammatory patients while preserving benefit in hyperinflammatory ARDS.
Key Findings
- An AI Clinical Classifier identified 39% hyperinflammatory and 61% hypoinflammatory ARDS using routine data.
- 30-day mortality was 49% in hyperinflammatory vs 24% in hypoinflammatory ARDS (p<0.001).
- Phenotypes evolved: 49% of hyperinflammatory patients converted to hypoinflammatory by day 30; 7% converted the other way.
- Corticosteroids reduced mortality in hyperinflammatory ARDS (IPW-weighted HR 0.81, p=0.033) but increased mortality in hypoinflammatory ARDS (HR 1.26, p=0.009).
- At day 3, survival benefit from steroids persisted only in patients remaining hyperinflammatory (adjusted OR 0.51, p=0.004).
Methodological Strengths
- Classifier developed from six multicenter RCT datasets and externally validated in a large cohort (n=5578).
- Use of discrete-time Bayesian Markov modeling and target trial emulation to address temporal stability and treatment effect.
Limitations
- Steroid effects were inferred from observational emulation rather than randomized allocation within phenotypes.
- Phenotype transitions may complicate real-time clinical decision-making and require workflow integration.
Future Directions: Prospective, phenotype-stratified randomized trials testing corticosteroid strategies with serial reclassification; integration of the classifier into ICU electronic systems to enable real-time guidance.
PURPOSE: Inflammatory phenotypes of acute respiratory distress syndrome (ARDS) can predict patient outcomes and potentially response to treatment. The aim was to assess whether inflammatory phenotypes can be characterized over time using clinical surrogate data and used to guide therapy with corticosteroids. METHODS: Individual patient data and biomarkers from six multicenter randomized controlled trials (development, n = 1207; validation, n = 2751) were analyzed to establish an open-source AI Clinical Classifier ( https://bostonmontpelliercare.shinyapps.io/AIClarity ) for inflammatory phenotypes of ARDS using routine clinical data. Then, patients from a retrospective cohort (investigation, n = 5578) underwent classification from baseline to day 30. A discrete-time Bayesian Markov model assessed temporal stability at 3-day intervals. A target trial emulation and longitudinal logistic regression assessed corticosteroid effect on 30-day mortality depending on phenotype. RESULTS: The AI Clinical Classifier identified 2169 (39%) hyperinflammatory and 3409 (61%) hypoinflammatory patients. 1053 (49%) and 826 (24%) patients died within 30 days, respectively (p < 0.001). Over 30 days, 49%(1072/2169) of hyperinflammatory patients at baseline transitioned to hypoinflammatory, and 7%(229/3409) of hypoinflammatory patients at baseline transitioned to hyperinflammatory (p < 0.001). Phenotypes predicted response to corticosteroids, with lower mortality in hyperinflammatory patients (IPW-weighted hazard ratio [HR]: 0.81 [0.67-0.98], p = 0.033), and higher mortality in hypoinflammatory patients (IPW-weighted HR: 1.26 [1.06-1.50], p = 0.009). At day 3, a positive response to corticosteroids only persisted among patients who remained hyperinflammatory (adjusted odds ratio = 0.51, 95% CI 0.32-0.80, p = 0.004). CONCLUSION: Characterization of inflammatory ARDS phenotypes using clinical surrogate data allows physicians to monitor patients throughout the course of the disease and guide clinical treatment. Corticosteroids may be beneficial in hyperinflammatory ARDS and harmful in hypoinflammatory ARDS.
2. Personalized driving pressure-guided positive end-expiratory pressure in patients at risk of postoperative respiratory failure (IMPROVE-2): a multicenter, pragmatic, randomized clinical trial.
In a 22-center, assessor-masked pragmatic RCT of emergency abdominal surgery patients, targeting driving pressure <13 cmH2O via individualized highest PEEP did not reduce the primary composite outcome and increased reintubation/curative NIV. Secondary outcomes were similar, challenging the clinical utility of a high-PEEP, driving pressure–guided strategy.
Impact: A high-quality pragmatic RCT provides negative evidence against a widely discussed ventilation approach, directly informing perioperative lung-protective strategies.
Clinical Implications: Avoid routinely escalating PEEP to achieve low driving pressure during emergency abdominal surgery; prioritize established lung-protective measures and monitor for need of reintubation/NIV.
Key Findings
- Primary composite outcome occurred in 25.7% (intervention) vs 20.2% (control), RR 1.27 (95% CI 0.96–1.68), p=0.08.
- Reintubation or need for curative NIV was higher with the intervention (difference 7.1%; RR 1.97; 95% CI 1.24–3.11; p=0.004).
- No significant differences in other secondary outcomes.
Methodological Strengths
- Multicenter, pragmatic, assessor-masked randomized design with trial registration.
- Clinically relevant endpoints in a high-risk surgical population.
Limitations
- Details on exact PEEP titration protocol and perioperative co-interventions are limited in the abstract.
- Generalizability beyond emergency abdominal surgery and to non-pragmatic settings remains to be established.
Future Directions: Evaluate alternative individualized ventilation strategies (e.g., imaging- or compliance-guided PEEP) and validate in broader surgical cohorts; explore mechanisms for increased reintubation/NIV.
PURPOSE: Airway driving pressure has garnered considerable attention for lung-protective ventilation. We evaluated the clinical effectiveness of airway driving pressure as a target to individualize positive-end-expiratory pressure (PEEP) setting in mechanically ventilated patients at risk for postoperative respiratory failure. METHODS: We conducted a multicenter, pragmatic, assessor-masked, randomized trial among adult patients undergoing emergency abdominal surgery in 22 hospitals in France. Patients were assigned 1:1 to receive individually adjusted highest PEEP targeting a driving pressure < 13 cmH RESULTS: The primary outcome occurred in 87 out of 338 (25.7%) intervention patients and in 69 out of 341 (20.2%) control patients (difference, 5.5%; 95% confidence interval [CI] - 0.8 to 11.8; relative risk, 1.27; 95%CI 0.96-1.68; p = 0.08). The difference was primarily due to an increased incidence of reintubation or need for curative non-invasive ventilation among intervention patients (difference, 7.1%; 95% CI 2.5-11.9; relative risk, 1.97; 95% CI 1.24-3.11; p = 0.004). Other secondary outcomes did not differ. CONCLUSION: Among patients at risk for postoperative respiratory failure after emergency abdominal surgery, a strategy of individually adjusted highest PEEP in targeting driving pressure lower than 13 cmH TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03987789.
3. Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
Across 21 retrospective studies (2,099 patients), strong predictors of RP-ILD in IIM included anti-MDA5 antibodies (OR 6.04), hyperferritinemia (OR 5.84), fever, pulmonary infection, and anti-Ro52. Longer disease duration and dysphagia were associated with lower RP-ILD risk.
Impact: Provides actionable risk stratification to identify IIM patients at high risk for rapidly progressive ILD, informing monitoring intensity and early aggressive therapy.
Clinical Implications: Screen IIM patients—especially those with anti-MDA5, high ferritin, fever, or pulmonary infection—for RP-ILD and consider early intensive immunosuppression and close respiratory monitoring.
Key Findings
- Anti-MDA5 antibodies (OR 6.044) and hyperferritinemia (OR 5.844) are strong risk factors for RP-ILD in IIM.
- Additional risks include clinically amyopathic dermatomyositis (OR 3.023), fever (OR 3.090), pulmonary infection (OR 2.610), anti-Ro52 (OR 2.425), and elevated LDH/CRP/AST/ALT.
- Longer disease duration (OR 0.790) and dysphagia (OR 0.773) were associated with lower RP-ILD risk.
Methodological Strengths
- Comprehensive search across four databases with predefined protocol and registration.
- Heterogeneity, sensitivity, and publication bias assessed (Egger’s test, trim-and-fill).
Limitations
- All included studies were retrospective, limiting causal inference and subject to confounding.
- Variability in RP-ILD definitions and clinical criteria across studies may contribute to heterogeneity.
Future Directions: Prospective, standardized cohort studies to validate risk models; evaluate whether risk-guided early aggressive therapy improves survival in RP-ILD.
OBJECTIVES: Interstitial lung disease (ILD), the main pulmonary manifestation of idiopathic inflammatory myopathy (IIM), frequently develops into rapidly progressive ILD (RP-ILD) with significantly worse prognosis. This meta-analysis identified risk and protective factors associated with developing RP-ILD in IIM patients. METHODS: PubMed, Embase, Web of Science, and Scopus (up to October 2024) were searched, analyzing 21 retrospective studies (2,099 patients). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were collected. Subgroup analysis was performed based on the RP-ILD definition. Sensitivity analysis and publication bias assessments (Egger's test and trim-and-fill method) were performed. RESULTS: The associated risk factors for RP-ILD development in IIM patients included age (OR = 1.014, 95% CI: 1.002-1.025), clinically amyopathic dermatomyositis (OR = 3.023, 95% CI: 1.491-6.130), mechanic's hands (OR = 1.421, 95% CI: 1.054-1.915), fever (OR = 3.090, 95% CI: 1.933-4.939), pulmonary infection (OR = 2.610, 95% CI: 1.457-4.677), anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibodies (OR = 6.044, 95% CI: 4.331-8.435), anti-Ro-52 antibodies (OR = 2.425, 95% CI: 1.807-3.255), and elevated levels of ferritin (OR = 5.844, 95% CI: 4.121-8.287), lactate dehydrogenase (OR = 3.627, 95% CI: 2.406-5.466), erythrocyte sedimentation rate (OR = 1.598, 95% CI: 1.089-2.344), aspartate transaminase (OR = 2.666, 95% CI: 1.864-3.814), alanine transaminase (OR = 2.702, 95% CI: 1.737-4.201), and C-reactive protein (OR = 3.366, 95% CI: 2.149-5.274), whereas longer disease duration (OR = 0.790, 95% CI: 0.638-0.977) and dysphagia (OR = 0.773, 95% CI: 0.653-0.916) were potential protective factors. CONCLUSION: This meta-analysis of 21 retrospective studies identified potential risk and protective factors associated with RP-ILD development in IIM patients, providing a basis for early identification and management. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/inplasy-2025-4-0059/, identifier INPLASY202540059.